Barclays PLC raised its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 1,275.5% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 14,993 shares of the biopharmaceutical company's stock after acquiring an additional 13,903 shares during the quarter. Barclays PLC's holdings in Xenon Pharmaceuticals were worth $590,000 at the end of the most recent quarter.
Other institutional investors also recently bought and sold shares of the company. Blue Trust Inc. increased its stake in shares of Xenon Pharmaceuticals by 174.7% in the 3rd quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company's stock worth $39,000 after purchasing an additional 641 shares in the last quarter. nVerses Capital LLC purchased a new stake in Xenon Pharmaceuticals in the third quarter worth about $102,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Xenon Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company's stock worth $106,000 after buying an additional 487 shares during the period. Quarry LP lifted its position in shares of Xenon Pharmaceuticals by 207.7% during the 2nd quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company's stock valued at $156,000 after buying an additional 2,700 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Xenon Pharmaceuticals during the 2nd quarter valued at approximately $464,000. Institutional investors own 95.45% of the company's stock.
Xenon Pharmaceuticals Stock Up 2.5 %
XENE stock traded up $0.97 during mid-day trading on Thursday, hitting $40.17. 546,200 shares of the company were exchanged, compared to its average volume of 389,289. The business has a fifty day simple moving average of $41.18 and a 200-day simple moving average of $40.52. The firm has a market capitalization of $3.06 billion, a P/E ratio of -14.24 and a beta of 1.19. Xenon Pharmaceuticals Inc. has a 12-month low of $35.53 and a 12-month high of $50.99.
Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) EPS for the quarter, topping analysts' consensus estimates of ($0.82) by $0.01. During the same period last year, the firm earned ($0.73) EPS. Research analysts predict that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.
Insider Activity at Xenon Pharmaceuticals
In related news, CFO Sherry Aulin sold 18,709 shares of the business's stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total transaction of $770,997.89. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gary Patou sold 4,891 shares of the firm's stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $41.08, for a total value of $200,922.28. Following the completion of the sale, the director now owns 23,573 shares in the company, valued at approximately $968,378.84. This represents a 17.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.52% of the company's stock.
Analysts Set New Price Targets
Several equities analysts have weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a report on Thursday, December 12th. Raymond James reiterated an "outperform" rating and set a $50.00 price objective on shares of Xenon Pharmaceuticals in a research report on Thursday, October 10th. Finally, Needham & Company LLC restated a "buy" rating and set a $60.00 price objective on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $56.00.
Get Our Latest Stock Analysis on Xenon Pharmaceuticals
About Xenon Pharmaceuticals
(
Free Report)
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
Featured Stories
Before you consider Xenon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xenon Pharmaceuticals wasn't on the list.
While Xenon Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
